Le Lézard
Classified in: Health
Subjects: AWD, AVO, CFG

Government of Canada Announces Semi-finalists of the Type 2 Diabetes Prevention Challenge


Innovators to help Canadian communities adopt healthy behaviours to reduce the risk of developing type 2 diabetes

OTTAWA, ON, Oct. 31, 2023 /CNW/ - Diabetes is one of the most prevalent chronic diseases in Canada, with over 3 million people living with diabetes and 200,000 new cases diagnosed every year. Diabetes has significant impacts, loss of eyesight, nerve damage and kidney disease, on the lives of the people that it directly affects, as well as on their families and broader communities.

Through Budget 2021 funding and in partnership with Impact Canada, PHAC launched the Type 2 Diabetes Prevention Challenge in Fall 2022 to attract innovators to develop and implement community, co-designed approaches to prevent type 2 diabetes. The Challenge, delivered through a three-stage approach, is focused on addressing the determinants of health and social barriers that can lead to an increased risk of developing type 2 diabetes, particularly in communities that are already at higher risk. This includes the social, economic and environmental determinants, such as access to healthy food, that contribute to health inequities and reducing the stigma that people at risk for type 2 diabetes tend to face.

Today, the Honourable Mark Holland, Minister of Health, announced the 20 semi-finalists selected to receive a $35,000 prize for proposing the most promising concept as part of the first-stage of the Type 2 Diabetes Prevention Challenge. During the second-stage of the challenge, these semi-finalists will develop their concept and create a fully implementable plan. The Challenge will ultimately empower Canadian communities, providing them with additional tools and resources to learn and adapt healthy behaviours to reduce the risk of developing type 2 diabetes, and help mitigate negative diabetes-related health conditions.

Quotes 

"We know we can do so much more for Canadians living with type 2 diabetes and for those at high risk. That's why we are working with Impact Canada and other partners on the diabetes challenge to promote new, innovative ways to address the risks that lead to developing type 2 diabetes. I would like to thank all participants for their hard work and offer my congratulations to the 20 semi-finalists of the Type 2 Diabetes Prevention Challenge. I look forward to following their progress and wish them luck in the next stage of the competition."

The Honourable Mark Holland
Minister of Health

"Congratulations to the 20 semi-finalists of Impact Canada's Type 2 Diabetes Prevention Challenge. Their transformative and innovative work will bring essential tools to support a better health future for Canadians and reduce their risk of developing type 2 diabetes."

The Honourable Harjit Sajjan
President of the King's Privy Council for Canada and Minister of Emergency Preparedness and Minister responsible for the Pacific Economic Development Agency of Canada

Quick Facts
Related links

SOURCE Public Health Agency of Canada


These press releases may also interest you

at 04:45
ERS Genomics Limited (?ERS'), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS' CRISPR/Cas9 patent portfolio....

at 03:15
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on haemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary haemostatic gel, VETIGEL®, to be sold directly...

at 02:30
Ahead of International Tea Day - 21st May 2024  - and with summer inspiring more of us to get off the sofa to be active, a 2024 real-world research study1 reviewed by the tea science experts at the Tea Advisory Panel ? www.teaadvisorypanel.com -...

at 02:30
TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1]...

at 02:20
Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis...

at 02:07
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....



News published on and distributed by: